Noteworthy - Pharmaceutical Executive



Checking the Box on Early Commercialization

January 10, 2014

Failure to improve successful launch rates will doom your company to marginalization in the fight for brand affinity — not to mention the prescriber loyalty that keeps medicines in play for the long haul.

US Pharma Challenges 2014

January 8, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing in the U.S. in 2014, writes Jill Wechsler.

The iPad's Future in Pharma

January 8, 2014

Three years into the Apple-led tablet era, the iPad is still being used as no more than a glorified touchscreen. Gabriel Cangiano, Ron Kane, and David Windhausen look at the key role it can play in the future of pharma.

Tracking Innovation in 2013's New Molecular Entities

January 6, 2014

Patricia Van Arnhum reviews 2013's crop of the new molecular entities and new biologics license applications approved by FDA.

The Climate Change in Outsourcing

January 2, 2014

Financial, political, and scientific developments that began 10 years ago are only now being felt by the biopharmaceutical contract services industry, writes Jim Miller.

Biotechnology Innovation and Growth in Israel

December 16, 2013

Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R&D, clinical research, and market growth.

2013 Pharma and Biotech Financial Report

December 1, 2013

Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better, writes Peter Young.

Executive Profile: United BioSource's Patrick Lindsay

December 1, 2013

For Patrick Lindsay, providing decision support across the full product life cycle is no stretch goal—it's today's fact of life

FDA Pursues Delicate Balancing Act

December 1, 2013

The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.


Click here